Impact Therapeutics (HKG:7630) Chief Executive Officer Sui Xiong Cai has purchased HK$1.6 million worth of the company's shares, according to a bourse filing on Thursday.
The oncology company disclosed that CEO Sui bought 100,000 shares at HK$1.61 apiece. Following the transaction, he held 18.5 million shares, or roughly a 6.6% stake in Impact.